Paratek Pharmaceuticals, Inc. (PRTK)
| Previous Close | 1.9000 |
| Open | 1.9300 |
| Bid | 1.8900 x 1800 |
| Ask | 1.9400 x 800 |
| Day's Range | 1.8400 - 1.9500 |
| 52 Week Range | 1.7900 - 11.2400 |
| Volume | |
| Avg. Volume | 556,595 |
| Market Cap | 96.865M |
| Beta (5Y Monthly) | 1.50 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.0970 |
| Earnings Date | Feb 22, 2022 - Feb 28, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Oct 31, 2014 |
| 1y Target Est | 18.50 |
- GlobeNewswire
Paratek Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced that Evan Loh, M.D., chief executive officer, will participate in a virtual fireside chat during the H.C. Wainwright Global Investment Conference. The conference will b
- Motley Fool
Paratek Pharmaceuticals (PRTK) Q1 2022 Earnings Call Transcript
Participants on today's call are Evan Loh, M.D, chief executive officer; Adam Woodrow, president and chief commercial officer; and Randy Brenner, chief development and regulatory officer. Michael Bigham, executive chairman, and I will also be available for questions.
- GlobeNewswire
Paratek Pharmaceuticals Announces First Quarter 2022 Revenue of $24.9 Million
-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $19.9 Million from the Core Commercial Business, a 51% Increase over First Quarter 2021 -- Omadacycline Demonstrated Potent In Vitro Efficacy Against Mycobacterium Avium Complex (MAC) in a Hollow Fiber Model BOSTON, May 04, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today reported financial results and provided an update on corporate activities for the quarter ended March 31, 2022. “Our commercial execution continue
